24th Symposium on Medicinal Chemistry in Eastern England


Thursday, 25th April 2013
Fielder Centre, Hatfield, Hertfordshire, UK

Speakers

Robert Sheppard
GlaxoSmithKline
Epigenetic modulation of the pro-inflammatory macrophage response - discovery of a selective Jumonji H3K27 demethylase inhibitor

Bernat Vidal
Almirall
Discovery of potent and selective Syk inhibitors for the treatment of asthma

Nigel Swain
Pfizer
Development of acidic molecules as drug candidates: A medicinal chemistry perspective

Mark Chambers
BioFocus
GNE-7915: A potent, selective and brain-penetrant LRRK2 inhibitor

Tom Hunt
Novartis
Discovery of a novel chemotype of ENaC blockers for the treatment of cystic fibrosis

David Clark
Argenta
From virtual to clinical: The discovery of the EP4 receptor antagonist, AP-1531

Richard Ward
AstraZeneca
Structure-based design of irreversible kinase inhibitors

Bertrand Heckmann
Galapagos
From PSK1404 to GLPG0187, clinical candidate: How to overcome toxicity in the integrin receptor antagonist program


Downloadable Files


PDF files require Link icon Adobe Acrobat Reader